Burstein H J, Bunnell C A, Winer E P
Department of Adult Oncology, Dana-Farber Cancer Institute, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Semin Oncol. 2001 Aug;28(4):344-58. doi: 10.1016/s0093-7754(01)90129-0.
Cytotoxic chemotherapy is important for treatment of women with hormone-insensitive or hormone-refractory advanced breast cancer. A variety of agents are effective, alone or in combination. The clinical activity and side effects of many agents, as well as principles for use of chemotherapy, are reviewed. Recent advances in chemotherapy for breast cancer include important studies on the role of dose-intensity, modifications of available agents to reduce side effects, and the availability of oral chemotherapeutics. Finally, the combination of chemotherapy with novel biological agents may improve outcomes for women with certain types of breast cancer. The growing availability of such biological therapies given in combination with chemotherapy may mean better survival in the future for women with advanced breast cancer.
细胞毒性化疗对于治疗激素不敏感或激素难治性晚期乳腺癌女性患者很重要。多种药物单独使用或联合使用均有效。本文综述了许多药物的临床活性和副作用,以及化疗的使用原则。乳腺癌化疗的最新进展包括关于剂量强度作用的重要研究、对现有药物进行改良以减少副作用,以及口服化疗药物的可获得性。最后,化疗与新型生物制剂联合使用可能会改善某些类型乳腺癌女性患者的治疗结果。越来越多的此类生物疗法与化疗联合使用,可能意味着晚期乳腺癌女性患者未来的生存率会提高。